Gilead Oncology Trodelvy Resources | Valuable Information and Support | GileadPro

For GB healthcare professionals only. This page contains promotional content
Adverse Event Reporting Prescribing Information

Download these useful resources to support your management of patients with metastatic triple-negative breast cancer who have been prescribed Trodelvy®.
Should you have any questions about these resources or want any printed copies please contact your Trodelvy® team.

trodelvy logo

Trodelvy®▼ (sacituzumab govitecan) patient guide

A guide for patients with metastatic triple-negative breast cancer receiving Trodelvy®. Topics include:
- How Trodelvy® works
- How Trodelvy® is given
- Practical treatment advice
- Key adverse effects and how to manage them
Download
trodelvy log

Trodelvy®▼ (sacituzumab govitecan) practical guide

An easy-to-follow guide that shows you how to:
- Dose and administer Trodelvy® as per the licensed indication
- Manage key adverse events, including diarrhoea, nausea and vomiting, and neutropenia
Download
Untitled-1

Trodelvy®▼ (sacituzumab govitecan) key data

A quick overview of the primary endpoint, efficacy and safety data for Trodelvy®.
Download

March 2024 UK-TRO-0922

Adverse events should be reported

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.